Crystallization and preliminary X-ray crystallographic studies of a new class of enoyl-(acyl-carrier protein) reductase, FabV, from Vibrio fischeri
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Ae Kyung | - |
dc.contributor.author | Lee, Jeong Hye | - |
dc.contributor.author | Chi, Young Min | - |
dc.contributor.author | Moon, Jin Ho | - |
dc.date.accessioned | 2021-09-06T23:38:49Z | - |
dc.date.available | 2021-09-06T23:38:49Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-01 | - |
dc.identifier.issn | 2053-230X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/109246 | - |
dc.description.abstract | Enoyl-(acyl-carrier protein) reductase (ENR) catalyzes the last step of the fatty-acid elongation cycle of the bacterial fatty-acid biosynthesis (FAS II) pathway. Recently, a new class of ENR has been identified from Vibrio cholerae and was named FabV. In order to understand the molecular mechanism of the new class of ENR at the structural level, FabV from V. fischeri was overexpressed, purified and crystallized. Diffraction data were collected to 2.7 angstrom resolution from a native crystal. The crystal belonged to the orthorhombic space group P21212, with unit-cell parameters a = 123.53, b = 164.14, c = 97.07 angstrom. The presence of four molecules of FabV in the asymmetric unit gave a VM value of 2.81 angstrom 3 Da-1, with a corresponding solvent content of 54.5%. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | INT UNION CRYSTALLOGRAPHY | - |
dc.subject | FATTY-ACID BIOSYNTHESIS | - |
dc.subject | ANTIBACTERIAL DRUG DISCOVERY | - |
dc.subject | MYCOBACTERIUM-TUBERCULOSIS | - |
dc.subject | ESCHERICHIA-COLI | - |
dc.subject | RESISTANT | - |
dc.subject | TARGETS | - |
dc.subject | STRAINS | - |
dc.title | Crystallization and preliminary X-ray crystallographic studies of a new class of enoyl-(acyl-carrier protein) reductase, FabV, from Vibrio fischeri | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chi, Young Min | - |
dc.identifier.doi | 10.1107/S1744309111049426 | - |
dc.identifier.scopusid | 2-s2.0-84862965247 | - |
dc.identifier.wosid | 000298951400019 | - |
dc.identifier.bibliographicCitation | ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, v.68, pp.78 - 80 | - |
dc.relation.isPartOf | ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS | - |
dc.citation.title | ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS | - |
dc.citation.volume | 68 | - |
dc.citation.startPage | 78 | - |
dc.citation.endPage | 80 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biophysics | - |
dc.relation.journalResearchArea | Crystallography | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biophysics | - |
dc.relation.journalWebOfScienceCategory | Crystallography | - |
dc.subject.keywordPlus | FATTY-ACID BIOSYNTHESIS | - |
dc.subject.keywordPlus | ANTIBACTERIAL DRUG DISCOVERY | - |
dc.subject.keywordPlus | MYCOBACTERIUM-TUBERCULOSIS | - |
dc.subject.keywordPlus | ESCHERICHIA-COLI | - |
dc.subject.keywordPlus | RESISTANT | - |
dc.subject.keywordPlus | TARGETS | - |
dc.subject.keywordPlus | STRAINS | - |
dc.subject.keywordAuthor | FAS II pathway | - |
dc.subject.keywordAuthor | enoyl-(acyl-carrier protein) reductase | - |
dc.subject.keywordAuthor | Vibrio fischeri | - |
dc.subject.keywordAuthor | FabV | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.